Vitro Diagnostics Inc (fka VODG)

[Potse]

510(k) application(s) expected in early 2013.....

According to the VODG website, the company expects to file a 510(k) application(s) sometime during early 2013. Also, interesting to note that endothelial cells are among the differentiated cells the company expects to include in its product line (see the above post regarding an endothelial differentiation medium the company has in the product development pipeline)........

Our current operational strategy involves expanding market penetration of our MSC research products together with considerable expansion of these products. We sell our products directly and through distributors as well. We are presently expanding our stem cell segment of our product line to include differentiated cells derived from MSCs including chondrocytes, endothelial cells and osteoblasts. These products are ideally suited for high through put screening in drug discovery, development and toxicology. We also are expanding our product line to include stem cell products with clinical applications. An initial target includes our MSC cell culture media for use in clinical studies. This includes serum-free, chemically-defined and animal-free media that allows cellular expansion with reduced concern about potential contamination. We have two products in this class that we plan to submit to FDA for approval in early 2013. We are also developing additional clinical products for use in the in-vivo imaging of stem cells and for treatment of articular, ligament and tendon injury in animals.

http://vitrobiopharma.com/about-us/corporate-overview/